Regenxbio Appoints Mitchell Chan as CFO

By Tamara Parker • Wednesday, September 18 07:56 • Permanent Link

Regenxbio Inc. (NASDAQ: RGNX) has appointed Mitchell Chan as its new Executive Vice President and Chief Financial Officer. Chan brings with him nearly two decades of experience in biopharmaceutical financial leadership, having previously served as the CFO of Viela Bio, Inc., where he oversaw a successful IPO and a $3 billion acquisition by Horizon Therapeutics. He has also held various financial and investor relations leadership roles at Astrazeneca and Genentech-Roche, among other companies.

Chan's appointment comes at an exciting time for Regenxbio as the company gears up for multiple catalysts across its late-stage gene therapy programs. The company is advancing a pipeline of AAV therapeutics for retinal and rare diseases, including treatments for wet AMD, diabetic retinopathy, Duchenne, and MPS II.

Mitchell Chan's extensive track record in driving finance organizations to support growth and his deep expertise in strategic planning and capital markets make him a valuable addition to Regenxbio's leadership team. His appointment follows the departure of Vit Vasista, who served as the company's CFO since 2009.

Vasista will continue to support the company through January 3, 2025, to ensure a smooth transition. Regenxbio's President and CEO, Curran Simpson, expressed gratitude for Vasista's dedication and significant contributions to the company, noting his instrumental role in taking the company public and ensuring it is positioned with a strong balance sheet and cash runway to support the next stage of its journey.

Regenxbio is a leading clinical-stage biotechnology company focused on the curative potential of gene therapy. Since its founding in 2009, the company has pioneered the development of AAV therapeutics, an innovative class of gene therapy medicines. Thousands of patients have been treated with Regenxbio's AAV therapeutic platform, including Novartis' Zolgensma® for children with spinal muscular atrophy. The company's AAV therapeutics are designed to be one-time treatments with the potential to change the way healthcare is delivered for millions of people. Today the company's shares have moved 1.6% to a price of $12.95. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.